|| List of recent Receptor-related patents
|Peptidic and non peptidic ligands for immunodetection of the receptor for urotensin ii|
The use of opportunely modified specific ligands of the receptor for urotensin ii (utr) or antibodies (commercially available) raised against the same receptor as tools for the definition of both the differentiation and the prognosis of human prostate adenocarcinoma is described, moreover, the use of opportunely radiolabeled ligands for utr in the definition of the extension of disease is also described.. .
|Pattern recognition receptor expression as a measure of systemic health|
The present invention encompasses methods and kits employing pattern recognition receptor expression as a measure of systemic health in a subject afflicted with an oral health condition. In particular, the present invention is directed to methods involving measurement of the expression levels of one or more pattern recognition receptors including but not limited to toll like receptors, myeloid differentiation primary response gene 88 (myd88), and nucleotide binding oligomerization domain containing protein 1 (nod1), in a companion animal, e.g., a dog or a cat, afflicted with an oral health condition.
Hill's Pet Nutrition, Inc
|Monoclonal antibodies against c-met|
Isolated monoclonal antibodies which bind to human c-met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed..
|Chimeric antigen receptors and immune cells targeting b cell malignancies|
The disclosure describes genetically engineered cd37 specific redirected immune effector cells expressing a chimeric antigen receptor (car) protein comprising an antigen binding domain derived from an antibody, a single chain antibody or portion thereof that binds cd37; a hinge region; a transmembrane domain and an intracellular signaling domain derived from human cd3ζ or fcrγ; and optionally one or more co-stimulatory intracellular signaling domains the invention includes nucleic acids, vectors and immune effector cells associated with the production of the car protein, as well as methods of treating b cell malignancies in humans by cellular immunotherapy.. .
Bluebird Bio, Inc.
|Use of dr6 antagonists to improve motor neuron disease|
The present invention relates to death receptor-6 (dr6) antagonists and methods of their use in improving motor neuron disease. Novel affinity enhanced anti-dr6 antibodies are also provided.
Biogen Ma Inc.
|Low affinity blood brain barrier receptor antibodies and uses therefor|
The present invention relates to antibodies that bind blood brain barrier receptors (bbb-r) and methods of using the same.. .
The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (vegfr2) and human angiopoietin-2 (ang2), and may be useful for treating cancer, especially solid tumors driven by vegfr2 and ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.. .
Eli Lilly And Company
|Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules|
Novel compounds carrying ligands capable of ligating to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as in various methods.
|Notch-based fusion proteins and uses thereof|
This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of notch4 receptor protein operably affixed to a half-life-increasing moiety.
The Trustees Of Columbia University In The City Of New York
|Insulinotropic peptide derivative with modified n-terminal charge|
The present invention relates to an insulinotropic peptide derivative with a modified n-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the n-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral ph.
Hanmi Pharm. Co., Ltd.
Amido compounds and their use as pharmaceuticals
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (mr), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess..
Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr
Compounds of formula (a) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (asgpr) targeting agents.. .
Fsh receptor antagonists
Or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders..
2,4-pyrimidinediamine compounds and their uses
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the ige and/or igg receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the ige and/or igg receptor signaling cascades.. .
Rigel Pharmaceuticals, Inc.
Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics
To compositions containing them, to the process for preparing them and to their use in pharmaceutical or cosmetic compositions.. .
Therapeutic prostaglandin receptor agonists
Described herein are compounds which can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, treating wounds, or other medical and/or cosmetic uses.. .
Compounds as lysophosphatidic acid receptor antagonists
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating lpa-dependent or lpa-mediated conditions or diseases..
Amira Pharmaceuticals, Inc.
Small molecule agonists of neurotensin receptor 1
Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.. .
Systems and methods for treating dyspnea, including via electrical afferent signal blocking
Systems and methods for treating a patient with dyspnea are disclosed. A method in accordance with a particular embodiment includes identifying the patient as suffering from dyspnea, and, based at least in part on identifying the patient as suffering from dyspnea, implanting an electrical signal delivery element within the patient in signal communication with an afferent neural pathway of a carotid body chemoreceptor.
Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody fab fragments, single chain antibodies, soluble vegf receptor-fc fusion proteins, and/or anti-angiogenic pdgf receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, vegf receptors, and/or pdgf receptors.
Neurotech Usa, Inc.
Compositions and methods comprising toll like receptor (tlr) stimulating agents for prophylaxis and therapy for damage to dermal epithelium
Provided are compositions and methods for prophylaxis and/or therapy of dermal damage. The compositions and methods involve toll like receptor (tlr) agonists that can inhibit the formation or accelerate healing of dermal damage, and/or inhibit inflammation at near the location of the dermal damage.
Cleveland Biolabs, Inc
Stilbenoid derivatives and their uses
The present invention generally provides stilbenoid derivatives and methods for using stilbenoid derivatives to modulate the activity of cannabinoid receptors or scavenge reactive nitrogen species.. .
Arkansas State University
Substituted 7-azabicycles and their use as orexin receptor modulators
Wherein ring a is phenyl, naphthalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyl, thiazolyl, isoxazolyl, pyrazolyl, imidazothiazolyl, benzimidazolyl, or indazolyl; r1 is h, alkyl, alkoxy, hydroxyalkylene, oh, halo, phenyl, triazolyl, oxazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyrrolidinyl, thiophenyl, morpholinyl, or dialkylamino; r2 is h, alkyl, alkoxy, hydroxyalkylene, or halo; z is nh, n-alkyl, or o; r5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinazolinyl, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, alkoxy, or halo; and n is 0 or 1. Methods of making the compounds of formula i are also described.
Compounds for protection of photoreceptor cells and for enhancing visual function under low light conditions
Described herein are methods of enhancing visual function under low light conditions and to methods of protecting photoreceptors cells by administration of a compound selected from the group consisting of zalospirone and eptapirone; or a pharmaceutically acceptable salt thereof.. .
2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
The invention relates to the compounds of general formula (i): preparation process and therapeutic use.. .
Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists
The present invention relates to methods of preventing or treating a staphylococcus infection comprising administering an effective amount of a peroxisome proliferator-activated receptor (ppar)-γ agonist. The invention further relates to methods of modulating a host wound response..
The University Of North Carolina At Chapel Hill
Method and pharmaceutical composition for inhibiting pi3k/akt/mtor signaling pathway
The present invention relates to a pharmaceutical composition of prcp antagonist, prep antagonist, or prcp-prep dual antagonist. The present invention also relates to a pharmaceutical composition jointly using prcp antagonist and mtor antagonist, or jointly using prep antagonist and mtor antagonist, or jointly using prcp-prep dual antagonist and mtor antagonist.
Targeted Therapeutics, Llc
Methods for administration and formulations for the treatment of regional adipose tissue
Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation comprising a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration.
Flip-cover receptor connector, and rf plate cable and cable end connector used in conjunction therewith
A flip-cover receptor connector, and a rf (radio frequency) plate cable and a cable end connector used in conjunction therewith are provided. A receptor insulator is provided concavely with a placement space.
Harumoto Technology (shen Zhen) Co., Ltd.
Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
The present invention relates generally to methods of in vitro diagnostics, in particular the use of a compound selected from the group consisting of fibroblast growth factor 23 (fgf23), inorganic phosphorus (p), the product of inorganic phosphorus and total calcium (p×tca), osteopontin (opn) and parathyroid hormone (pth) as biomarker. Said biomarkers can be used to monitor the modulation of fibroblast growth factor receptor (fgfr) kinase activity, in particular its inhibition, and/or the occurrence of secondary effects of fgfr inhibition.
Detection device for in vivo and/or in vitro enrichment of sample material
The invention relates to a detection device for in vivo and/or in vitro enrichment of sample material, including a functional surface equipped with detection receptors, in which the functional surface is located directly or indirectly on a measuring structure that includes optically conductive material for optical measurement of target molecules enriched on the detection receptors.. .
Method for measuring thrombin generation
It is an object of the present invention to provide a measurement method capable of easily evaluating combined effects in a single assay system, when antithrombotic agents having different mechanisms of action are used in combination. A method for measuring thrombin generation comprising: (1) a step of adding an anticoagulant, a p2y12 receptor inhibitor, adenosine diphosphate and tissue factor to platelet rich plasma; (2) a step of adding a fluorogenic thrombin substrate and a calcium-containing solution thereto; and (3) a step of measuring fluorescence intensity..
Daiichi Sankyo Company, Limited
Angiopoietin-2 specific tie2 receptor
In one aspect, provided herein is a polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the polypeptide binds preferentially to angiopoietin-2 compared to angiopoietin-1. Nucleic acid sequences encoding the polypeptide, as well as pharmaceutical uses of the polypeptide in treating diseases such as cancer and inflammation are also provided..
University Of Leicester
Enhancing activity of car t cells by co-introducing a bispecific antibody
The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a t cell, genetically modified to express a chimeric antigen receptor (car), a bispecific antibody, or a combination thereof to a subject.
The Trustees Of The University Of Pennsylvania
Recombinant human igm-antibody effective against cancer cells
A recombinant human monoclonal pentameric igm antibody comprising the capability of oligospecific binding to purified ganglioside epitopes gd3, gm3, gd2 and gm1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the igm antibody; and the use of the igm antibody as a diagnostic tool and/or as a therapeutic agent.. .
Antibodies that modulate insulin receptor signaling are provided.. .
Xoma Technology Ltd.
Fragment of humanized anti-egfr antibody substituted-lysine variable fragment and use thereof
The purpose of the present invention is to provide fragments of humanized anti-egfr antibody substituted-lysine light-chain or heavy-chain variable regions, and single-chain antibodies, etc, comprising the same, having sufficient binding activity (affinity) with target cells, and having the ability to undergo various site-specific and uniform chemical modifications. The present invention pertains to a humanized variable region on the light-chain or heavy-chain of antibody 528 against human epidermal cell growth factor receptor 1 (her-1), said variable region comprising the amino acid sequence represented by seq id no: 2 or seq id no: 4, wherein fragments of humanized anti-egfr antibody lysine-substituted light-chain variable regions are formed by substituting a different amino acid for all of the lysine residues, or all of the lysine residues except for the lysine residue(s) of one specified moiety..
Hla-restricted, peptide-specific binding proteins
Antigen binding proteins with tcr-like paratopes, that is, with an antigen binding region specific for an hla-a2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv fragments.
Memorial Sloan Kettering Cancer Center
Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
The present invention relates to the prevention and/or treatment of arthritic, inflammatory and/or allergic reactions as well as thrombocytopenia, by blocking the human receptors fcyri and fcyriia. It is disclosed a mouse monoclonal antibody (mab) which efficiently blocks human fcyri and can therefore be used, alone or in a combination product, for example with an anti-hfcyriia blocking antibody, in the prevention and/or the treatment of these diseases..
Blood brain barrier shuttle
The present invention relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (r/bbb) and methods of using the same.. .
Hoffmann-la Roche Inc.
Methods of using il-1beta compounds
This invention relates to methods employing il-1β-ligand/il-1 receptor disrupting compounds (herein referred to as “il-1beta compounds”); such as small molecular compounds disrupting il-1β ligand-il-1 receptor interaction, il-1β antibodies or il-1 receptor antibodies, e.g. Il-1β binding molecules as described herein, e.g.
T1r taste receptors and genes encoding same
Newly identified mammalian taste-cell-specific g protein-coupled receptors, and the genes and cdna encoding said receptors are described. Specifically, t1r g protein-coupled receptors active in taste signaling, and the genes and cdna encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors.
Production of therapeutic proteins in genetically modified mammalian cells
The invention relates to methods for the production of therapeutic proteins in mammalian cells. In one embodiment, the method comprises producing a therapeutic protein such as igf-1 in a mammalian cell endogenously expressing a cognate receptor of said recombinant therapeutic protein and wherein binding of said therapeutic protein to said cognate receptor results in a low titer of the therapeutic protein, the method comprising with a mammalian cell being deficient in the expression of the cognate receptor of said therapeutic protein and being transformed with an expression vector comprising a nucleic acid molecule encoding the therapeutic protein: a.
Peptidic dual glp-1/glucagon receptor agonists derived from exendin-4
The present invention relates to dual glp-1/glucagon receptor agonists or optionally trigonal glp-1/glucagon/gip receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Dual glp-1/glucagon receptor agonists derived from exendin-4
The present invention relates to dual glp-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Fgf-2 variants having n-terminal deletions and increased receptor selectivity and uses thereof
The present invention relates to the design, manufacture and use of fibroblast growth factor (fgf) polypeptides having improved receptor specificity. In particular, the invention relates to isolated fgf2 and fgf4 polypeptides comprising a truncated n-terminus and optionally n-terminal amino acid substitutions.
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
The present disclosure provides a method for enhancing the anti-tumor efficacy of an fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a t cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the fc region of the fc fusion protein so as to enhance the binding of said fc region to an activating fc receptor (fcr). The disclosure also provides an fc fusion protein produced by said method which has an enhanced ability to potentiate an endogenous immune response against cells of a cancer or an infectious agent in a subject.
Bristol-myers Squibb Company
And the pharmaceutically acceptable salts and solvates thereof, wherein r1, r2, r3, r4, and r5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems.
Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands
The disclosure provides compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders..
Bristol-myers Squibb Company
4-fluoropiperidine orexin receptor antagonists
The present invention is directed to 4-fluoropiperidine compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved..
Merck Sharp & Dohme Corp.
Selective androgen receptor modulators
This invention provides compounds of formula i, pharmaceutical compositions comprising a compound of formula i and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same.. .
Radius Health, Inc.
Oxytocin receptor agonists for the treatment of cns diseases
Or a pharmaceutically acceptable acid addition salt, or a racemic mixture or its corresponding enantiomer and/or optical isomers thereof, for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .
Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
The invention relates to a pharmaceutical composition comprising a leukotriene antagonist or a leukotriene receptor antagonist for the treatment of a subject suffering from dementia in parkinson's disease. Further, the invention provides a pharmaceutical composition comprising a leukotriene antagonist or a leukotriene receptor antagonist for retrieval or improvement of learning processes or learning deficits and/or the prevention, retrieval or improvement of memory loss or memory impairment in a subject suffering from dementia in parkinson's disease.
Pyrrolidine gpr40 modulators
Or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are gpr40 g protein-coupled receptor modulators which may be used as medicaments..
2-pyridyloxy-4-nitrile-4-substituted orexin receptor antagonists
The present invention is directed to 2-pyridyloxy-3-nitrile-4-substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-nitrile-4-substituted compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.
3-ester-4 substituted orexin receptor antagonists
The present invention is directed to 3-ester-4-substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 3-ester-4-substituted compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.
2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
The present invention is directed to 2-pyridylamino-4-nitrile-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridylamino-4-nitrile-piperidinyl compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.
Indole carboxamide derivatives as p2x7 receptor antagonist
Wherein r1, r2, r3, r4, r5 and r6 are as defined in the description, their preparation and their use as pharmaceutically active compounds.. .
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
Provided herein are glucagon superfamily peptides conjugated with nhr ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention.
Indiana University Research And Technology Corporation
Pharmaceutical composition comprising antiemetic compounds and polyorthoester
The present disclosure provides for sustained release pharmaceutical formulations which can deliver both a 5-hydroxytryptamine 3 (5ht3) receptor antagonist and a neurokinin-1 (nk1) receptor antagonist to a subject in need thereof. Formulations described herein are suitable for subcutaneous administration.
Heron Therapeutics, Inc.
Egfr targeted therapy of neurological disorders and pain
The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to the epidermal growth factor receptor (egfr) as a clinical target for treatment of neurological disorders, preferably in conjunction with neuropathic pain.
Sykehuset SØrlandet Hf
New itch treatment using a combination of neurokinin-1, gastrin releasing peptide, and glutamate receptor antagonists
Methods, and compositions are provided for inhibition of histamine and non-histamine dependent itch signal transmission or scratch behavior. In one aspect, the present invention further comprises administering to the subject an inhibitor of histamine-dependent itch signal transmission.
The Regents Of The University Of California
Novel use of rice, rice bran or rice hull extract as an histamine receptor antagonist
Disclosed is a use of rice, rice bran or rice hull extract as a histamine receptor antagonist. The rice, rice bran or rice hull extract may be used as a natural antihistamine to prevent or treat allergic rhinitis, inflammatory bowel disease, asthma, bronchitis, nausea, gastric and duodenal ulcer, gastroesophageal reflux disease, sleep disorder, anxiety and depression.
Korea Food Research Institute
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
Cytotoxic lymphocytes expressing chimeric antigen receptors (car) that target and bind small conjugate molecules (scm) are disclosed, as well as methods of using the cells and the scms in the treatment of cancer.. .
Purdue Research Foundation
Novel compositions and methods for treating prostate cancer
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. In some embodiments, the solid matrix comprises a polymer.
Tokai Pharmaceuticals, Inc.
Copper intrauterine device
The invention relates to a copper contraceptive intrauterine system (ius) with a flexible frame, which system is further capable of releasing a selective progesterone receptor modulator (sprm), such as ulipristal acetate, for reducing or preventing bleeding side effects.. .
The Population Council, Inc.
Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
Which possess inhibitory activity against activating mutant forms of egfr, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man..
Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.. .
Galderma Research & Development
Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.. .
Merck Sharp & Dohme Corp.
Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
Administration of a 1-phenylalkanecarboxylic acid before, after, or a concurrently with a therapeutically effective amount of one or more of the following: (1) β-amyloid peptides level reducers, (2) pathogenic level tau reducers, (3) microtubule stabilizers, (4) agents capable or removing atherosclerotic plaques, (5) agents that lower circulating levels of β-amyloid and tau, (6) modulators of autophagy, (7) neurotransmitter levels regulators, (8) gaba(a) α5 receptor antagonists, and (9) additional agents that help maintain and/or restore cognitive function and functional deficits of ad, and/or slow down decline in cognitive functions and functional deficits in ad, is useful for prevention or therapeutical treatment of proteinopathies and/or neurodegenerative diseases.. .
Chiesi Farmaceutici S.p.a.
Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
The present invention relates to a pharmaceutical composition comprising, in at least one pharmaceutically acceptable support or vehicle, a combination of (3s,3s′)4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin i converting enzyme inhibitors and angiotensin ii receptor type i antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions..
Inserm(institut National De La Sant'e Et De La Recherche Medicale)
Solar photovoltaic panel and solar photovoltaic system
A solar photovoltaic panel disposed in a matrix for use, wherein the solar photovoltaic panel comprises a plurality of antennas configured to communicate with antennas placed on adjoining solar photovoltaic panels, a receptor configured to receive a search command via the plurality of antennas, a transmitter configured to transmit a search command from the antennas excluding the antenna having received the search command in response to the received search command, and a responder configured to create a response signal including the panel id of its own solar photovoltaic panel and transmit the response signal from the antenna having received the search command when no response signal to the search command transmitted from the transmitter is received, and when a response signal to the search command transmitted from the transmitter is received, transmit the response signal with the addition of information from the antenna having received the search command.. .
Mitsubishi Electric Corporation
Human notch receptor mutations and their use
The present invention provides the identification and characterization of notch mutations associated with enhanced receptor signaling. The present invention provides methods and kits for using the same.
Oncomed Pharmaceuticals, Inc.
Treatment of egf-receptor dependent pathologies
Disclosed are methods for treating a subject with an egfr dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent (“first agent”) that decreases the biological activity of irhom1 and an effective amount of an agent (“second agent”) that decreases the biological activity of irhom2.
University Health Network
Antipsychotic treatment based on drd2 or ankk1 snp genotype
The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (snp) associated with the dopamine receptor d2 (drd2) and/or ankyrin repeat and kinase domain containing 1 (ankk1) genes.. .
Vanda Pharmaceuticals, Inc.
Transferrin/transferrin receptor-mediated sirna delivery
The invention provides interfering rna molecule-ligand conjugates useful as a delivery system for delivering interfering rna molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (tfr).
Arrowhead Research Corporation
Compositions and methods for selective delivery of oligonucleotide molecules to cell types
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes..
Nlife Therapeutics, S.l.
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type iii deletion mutant, egfrviii. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to egfrviii.
Amgen Fremont Inc.
Human cdr-grafted antibody and antibody fragment thereof
A human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human cc chemokine receptor 4 (ccr4) but does not react with a human blood platelet; a human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of ccr4 and has a cytotoxic activity against a ccr4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.. .
Kyowa Hakko Kirin Co., Ltd.
Anti-ox40 antibodies and methods of using the same
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human ox40 are disclosed. Preferred antibodies have high affinity for ox40 receptor and activate the receptor in vitro and in vivo.
Board Of Regents, The University Of Texas System
Novel interleukin-33 inhibitors
The present invention relates to novel inhibitors of il-33. More specifically, it relates to a fusion protein of the soluble il-33 receptor with the soluble il-1racp as inhibitor of il-33 activity.
Exendin-4 derivatives as peptidic dual glp-1/glucagon receptor agonists
The present invention relates to dual glp-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Genetically encoded calcium indicators and methods of use
Genetically encoded calcium indicator (geci) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of g-protein coupled receptor (gpcr) or ion channels and methods of monitoring neural activity also are provided..
Howard Hughes Medical Institute
High-affinity peptide-based anticancer vaccination to overcome tumor resistance to immunostimulatory antibodies and to identify tcrs that can be used successfully in adoptive t cell therapy
The invention provides a methodology to use cancer vaccination to overcome tumor resistance to immunostimulatory antibodies. Our cancer vaccination approach relies on targeting mutant tumor-specific peptides that have high affinity for the major histocompatibility complex.
Mu opioid receptor agonist analogs of the endomorphins
The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2.
The Administrators Of The Tulane Educational Fund
Nmda receptor modulators and uses thereof
Disclosed are compounds having enhanced potency in the modulation of nmda receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.
Provided is a compound which is useful as an agent for treating or preventing 5-ht2c receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-ht2c receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-ht2c receptor agonist activity, thereby completing the present invention.
Astellas Pharma Inc.
Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
And their use as therapeutic compounds.. .
Substituted pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma receptors ligands
The present invention relates to new substituted pyrazolo[3,4-d]pyrimidine compounds, having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.. .
Laboratorios Del Dr. Esteve, S.a.
Compounds and methods for treatment of hypertension
Hydrogenated pyrido[4,3-b]indoles and pyrido[3,4-b]indoles are described. The compounds may bind to and are adrenergic receptor α2b antagonists.
Medivation Technologies, Inc.
Novel octahydropyridoquinazoline derivative, pharmaceutical composition containing same, and uses for said deriavative and composition
In which r1 is c1-6 alkyl or the like; r2 is hydrogen or the like; r3 and r4 are each hydrogen, c1-6 alkyl, r10r11n—c1-6 alkyl, aralkyl, or the like; r5 and r6 are hydrogen or the like; and r7 is hydrogen or the like, or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same and uses for said compound/salt and composition. The compounds of the present invention exhibit potent dopamine d2 receptor simulating activities and thus are useful as a treating or preventing agent for parkinson's disease and the like..
Kinase inhibitors and methods of their use
New compounds, compositions and methods of inhibition of provirus integration of maloney kinase (pim kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one pim kinase.
New positive allosteric modulators of nicotinic acetylcholine receptor
The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (pams) of the nicotinic acetylcholine α7 receptor..
H. Lundbeck A/s
And/or a salt thereof; wherein r is —oh or —op(o)(oh)2. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.